Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
LGVN Longeveron	$0.81 +6.4%	$1.35	$0.63 ▼ $2.86	$12.28M	0.23	506,359 shs	1.02 million shs
PHXM PHAXIAM Therapeutics	$3.10	$3.10	$2.50 ▼ $13.00	$10.58M	2.35	2,472 shs	N/A
RDHL Redhill Biopharma	$1.44 +5.9%	$1.78	$1.06 ▼ $12.50	$3.31M	4.18	315,420 shs	931,831 shs
SONN Sonnet BioTherapeutics	$3.35 -5.4%	$3.41	$1.08 ▼ $19.30	$10.62M	1.04	1.66 million shs	194,281 shs

These 7 Stocks Will Be Magnificent in 2025

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
LGVN Longeveron	0.00%	+12.11%	-50.00%	-45.71%	-67.66%
PHXM PHAXIAM Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%
RDHL Redhill Biopharma	0.00%	+17.24%	-26.88%	-28.42%	-99.25%
SONN Sonnet BioTherapeutics	0.00%	+9.94%	-42.72%	+170.23%	-32.70%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
LGVN Longeveron	3.6769 of 5 stars	3.5	5.0	0.0	0.0	2.9	1.7	1.3
PHXM PHAXIAM Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
RDHL Redhill Biopharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SONN Sonnet BioTherapeutics	2.9058 of 5 stars	3.5	4.0	0.0	0.0	1.0	0.0	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
LGVN Longeveron	3.00	Buy	$7.25	796.17% Upside
PHXM PHAXIAM Therapeutics	0.00	N/A	N/A	N/A
RDHL Redhill Biopharma	0.00	N/A	N/A	N/A
SONN Sonnet BioTherapeutics	3.00	Buy	$20.00	497.01% Upside

Current Analyst Ratings Breakdown

Latest RDHL, PHXM, LGVN, and SONN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
8/15/2025	LGVN Longeveron	Roth Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$10.00 ➝ $3.00

(Data available from 8/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
LGVN Longeveron	$2.39M	5.14	N/A	N/A	$1.47 per share	0.55
PHXM PHAXIAM Therapeutics	N/A	N/A	N/A	N/A	$7.98 per share	N/A
RDHL Redhill Biopharma	$8.04M	0.41	N/A	N/A	($3.66) per share	-0.39
SONN Sonnet BioTherapeutics	$20K	530.98	N/A	N/A	($0.71) per share	-4.72

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
LGVN Longeveron	-$15.97M	-$6.28	N/A	N/A	N/A	-894.40%	-95.91%	-79.69%	N/A
PHXM PHAXIAM Therapeutics	-$240K	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
RDHL Redhill Biopharma	-$8.27M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
SONN Sonnet BioTherapeutics	-$7.44M	N/A	0.00	∞	N/A	N/A	-4,646.10%	-342.21%	N/A

Latest RDHL, PHXM, LGVN, and SONN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/13/2025	Q2 2025	LGVN Longeveron	-$0.35	-$0.33	+$0.02	-$0.33	$0.41 million	$0.32 million
8/13/2025	Q3 2025	SONN Sonnet BioTherapeutics	-$0.49	-$0.95	-$0.46	-$0.95	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
LGVN Longeveron	N/A	N/A	N/A	N/A	N/A
PHXM PHAXIAM Therapeutics	N/A	N/A	N/A	N/A	N/A
RDHL Redhill Biopharma	N/A	N/A	N/A	N/A	N/A
SONN Sonnet BioTherapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
LGVN Longeveron	N/A	3.43	3.43
PHXM PHAXIAM Therapeutics	0.23	1.78	N/A
RDHL Redhill Biopharma	N/A	0.54	0.37
SONN Sonnet BioTherapeutics	N/A	0.26	0.26

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
LGVN Longeveron	10.01%
PHXM PHAXIAM Therapeutics	0.40%
RDHL Redhill Biopharma	7.20%
SONN Sonnet BioTherapeutics	9.45%

Insider Ownership

Company	Insider Ownership
LGVN Longeveron	11.20%
PHXM PHAXIAM Therapeutics	1.94%
RDHL Redhill Biopharma	6.81%
SONN Sonnet BioTherapeutics	2.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
LGVN Longeveron	20	15.18 million	13.48 million	Not Optionable
PHXM PHAXIAM Therapeutics	49	3.41 million	3.35 million	No Data
RDHL Redhill Biopharma	210	2.30 million	2.14 million	No Data
SONN Sonnet BioTherapeutics	10	3.17 million	3.10 million	Not Optionable

RDHL, PHXM, LGVN, and SONN Headlines

Recent News About These Companies

Sonnet Biotherapeutics Faces Earnings Volatility with New HYPE Treasury Strategy and Accounting Standards

August 15 at 7:34 AM | msn.com

Sonnet BioTherapeutics (SONN) Expected to Announce Earnings on Wednesday

August 12, 2025 | americanbankingnews.com

Sonnet Releases Virtual Investor "What This Means" Segment

August 11, 2025 | globenewswire.com

This Cancer Biotech Company Is Making a Big Bet on the HYPE Crypto. Should You Buy Its Stock Here?

August 6, 2025 | msn.com

Sonnet BioTherapeutics Expands Clinical Evaluation of SON-1010 Dose Escalation with Atezolizumab in Ovarian Cancer

August 4, 2025 | globenewswire.com

Beyond BTC and ETH: The Companies Turning to Alternative Crypto Treasury Assets

August 2, 2025 | msn.com

Sonnet BioTherapeutics Appoints Interim CEO Raghu Rao

August 1, 2025 | tipranks.com

Solana-based treasury model goes global as DeFi Development launches franchise

July 17, 2025 | msn.com

WLFI tokens to become tradable after World Liberty holders’ vote

July 17, 2025 | msn.com

Hyperliquid Strategies Inc. plan for $583M treasury boosts HYPE price

July 16, 2025 | cointelegraph.com

Sonnet BioTherapeutics Merges in $888M Deal to Launch Hyperliquid Strategies and HYPE Treasury

July 15, 2025 | thecurrencyanalytics.comT

Sonnet BioTherapeutics Stock Jumps 82% After Deal With Rorschach I: Retail Stays Exuberant

July 15, 2025 | msn.com

Public Firm Sonnet BioTherapeutics to Launch HyperLiquid Treasury in New Deal

July 14, 2025 | coinspeaker.com

Sonnet BioTherapeutics Shares Climb After Plan to Transfer Into Public Crypto Treasury Co.

July 14, 2025 | marketwatch.com

Why did Sonnet BioTherapeutics (SONN) Shares Gain over 200% in Premarket Trading?

July 14, 2025 | tokenist.comT

Hyperliquid Price Forecast: HYPE eyes gains following Sonnet BioTherapeutics' rebrand

July 14, 2025 | fxstreet.com

HYPE coin price up 200%, Sonnet BioTherapeutics merges into Hyperliquid Strategies

July 14, 2025 | msn.com

Massive deal sends biotech stock rallying 367%

July 14, 2025 | msn.com

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Sonnet BioTherapeutics, Inc. (NASDAQ: SONN)

July 14, 2025 | globenewswire.com

Why Is Sonnet BioTherapeutics Stock Trading Higher On Monday?

July 14, 2025 | benzinga.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

RDHL, PHXM, LGVN, and SONN Company Descriptions

Longeveron NASDAQ:LGVN

$0.81 +0.05 (+6.45%)

Closing price 04:00 PM Eastern

Extended Trading

$0.79 -0.02 (-2.10%)

As of 07:00 PM Eastern

Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company's lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors. It is conducting Phase 1, Phase 1/2, Phase 2a, and Phase 2b clinical trials in various indications, such as aging-related frailty, alzheimer's disease, and hypoplastic left heart syndrome. Longeveron Inc. was incorporated in 2014 and is headquartered in Miami, Florida.

PHAXIAM Therapeutics NASDAQ:PHXM

$3.10 0.00 (0.00%)

As of 08/15/2025

PHAXIAM Therapeutics S.A., a biopharmaceutical company, focuses on developing treatments for resistant bacterial infections in France and the United States. It develops eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing a portfolio of phages targeting resistant and dangerous bacteria, which together account for more than two-thirds of resistant hospital-acquired infections, including staphylococcus aureus, escherichia coli, and pseudomonas aeruginosa. The company was formerly known as ERYTECH Pharma S.A. and changed its name to PHAXIAM Therapeutics S.A. in June 2023. PHAXIAM Therapeutics S.A. was incorporated in 2004 and is headquartered in Lyon, France.

Redhill Biopharma NASDAQ:RDHL

$1.44 +0.08 (+5.88%)

Closing price 04:00 PM Eastern

Extended Trading

$1.37 -0.07 (-4.86%)

As of 06:07 PM Eastern

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, advanced unresectable cholangiocarcinoma, prostate cancer, and nuclear radiation protection; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 for pulmonary nontuberculous mycobacteria infections caused by mycobacterium avium complex. The company was incorporated in 2009 and is headquartered in Tel Aviv, Israel.

Sonnet BioTherapeutics NASDAQ:SONN

$3.35 -0.19 (-5.37%)

Closing price 04:00 PM Eastern

Extended Trading

$3.43 +0.08 (+2.39%)

As of 06:53 PM Eastern

Sonnet BioTherapeutics Holdings, Inc., a biotechnology company, owns a platform for biologic medicines of single or bifunctional action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead product candidate is SON-1010, a fully human single-chain version of interleukin 12 that is in Phase 1b/2a clinical trial for the treatment of solid tumor indications, including ovarian cancer, non-small cell lung cancer, and head and neck cancer. The company is also developing SON-080, a fully human version of interleukin 6, which is in Phase 1b/I2a clinical trail to treat chemotherapy-induced peripheral neuropathy and diabetic peripheral neuropathy; and SON-1210, a bispecific compound for solid tumor indications, including colorectal cancer. It has a license agreement with New Life Therapeutics Pte, LTD. to develop and commercialize pharmaceutical preparations containing a specific recombinant human interleukin-6; and strategic development collaboration with Sarcoma Oncology Center to advance SON-1210. The company is headquartered in Princeton, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time